4//SEC Filing
Adcock Richard 4
Accession 0001326110-24-000007
CIK 0001326110other
Filed
Jan 2, 7:00 PM ET
Accepted
Jan 3, 9:40 PM ET
Size
9.2 KB
Accession
0001326110-24-000007
Insider Transaction Report
Form 4
Adcock Richard
DirectorCEO & President
Transactions
- Exercise/Conversion
Common Stock
2023-12-31+34,483→ 220,065 total - Tax Payment
Common Stock
2023-12-31$5.02/sh−17,096$85,822→ 202,969 total - Exercise/Conversion
Restricted Stock Units
2023-12-31−34,483→ 120,697 total→ Common Stock (34,483 underlying)
Footnotes (3)
- [F1]On December 31, 2023, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on December 29, 2023 was the settlement price used to calculate the shares withheld.
- [F2]Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
- [F3]Five percent (5%) of the 172,420 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026.
Documents
Issuer
ImmunityBio, Inc.
CIK 0001326110
Entity typeother
Related Parties
1- filerCIK 0001830328
Filing Metadata
- Form type
- 4
- Filed
- Jan 2, 7:00 PM ET
- Accepted
- Jan 3, 9:40 PM ET
- Size
- 9.2 KB